WO2003070229A3 - Use of proteinase inhibitors in the treatment of autoimmune diseases - Google Patents

Use of proteinase inhibitors in the treatment of autoimmune diseases Download PDF

Info

Publication number
WO2003070229A3
WO2003070229A3 PCT/EP2003/001807 EP0301807W WO03070229A3 WO 2003070229 A3 WO2003070229 A3 WO 2003070229A3 EP 0301807 W EP0301807 W EP 0301807W WO 03070229 A3 WO03070229 A3 WO 03070229A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
autoimmune diseases
proteinase inhibitors
activation
diseases
Prior art date
Application number
PCT/EP2003/001807
Other languages
German (de)
French (fr)
Other versions
WO2003070229A2 (en
Inventor
Uwe Jacob
Peter Sondermann
Robert Huber
Original Assignee
Max Planck Gesellschaft
Uwe Jacob
Peter Sondermann
Robert Huber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10241411A external-priority patent/DE10241411A1/en
Application filed by Max Planck Gesellschaft, Uwe Jacob, Peter Sondermann, Robert Huber filed Critical Max Planck Gesellschaft
Priority to AU2003206945A priority Critical patent/AU2003206945A1/en
Publication of WO2003070229A2 publication Critical patent/WO2003070229A2/en
Publication of WO2003070229A3 publication Critical patent/WO2003070229A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the use of at least one substance that inhibits proteases and especially serine proteases in the treatment of diseases or conditions that are characterized by exuberant immune reactions, especially in excessive or undesired activation of immune cells, production of antibodies or activation of complements.
PCT/EP2003/001807 2002-02-22 2003-02-21 Use of proteinase inhibitors in the treatment of autoimmune diseases WO2003070229A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003206945A AU2003206945A1 (en) 2002-02-22 2003-02-21 Use of proteinase inhibitors in the treatment of autoimmune diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10207744 2002-02-22
DE10207744.4 2002-02-22
DE10241411.4 2002-09-06
DE10241411A DE10241411A1 (en) 2002-02-22 2002-09-06 Use of proteinase inhibitors for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
WO2003070229A2 WO2003070229A2 (en) 2003-08-28
WO2003070229A3 true WO2003070229A3 (en) 2004-03-04

Family

ID=27758411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001807 WO2003070229A2 (en) 2002-02-22 2003-02-21 Use of proteinase inhibitors in the treatment of autoimmune diseases

Country Status (2)

Country Link
AU (1) AU2003206945A1 (en)
WO (1) WO2003070229A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219039A1 (en) 2002-03-11 2003-09-22 Curacyte Ag Urokinase inhibitors, production and use thereof
DE10301300B4 (en) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein
DE10322191B4 (en) * 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylated amino acid derivatives, process for their preparation and their use
DE10342108A1 (en) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basic substituted benzylamine analogs as coagulation factor Xa inhibitors, their preparation and use
MX2008002702A (en) * 2005-08-29 2008-03-18 Wilex Ag Oxadiazole compounds as urokinase inhibitors.
DE102006050672A1 (en) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations
US20120172375A1 (en) * 2008-11-07 2012-07-05 Bruce Trapp Compounds and methods of promoting oligodendrocyte precursor differentiation
WO2012004678A2 (en) * 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
DE102011108346A1 (en) * 2011-07-25 2013-01-31 Philipps-Universität Marburg Use of inhibitors of TMPRSS2 as a drug
US11130780B2 (en) 2015-03-09 2021-09-28 Washington University Inhibitors of growth factor activation enzymes
KR20200031567A (en) * 2017-07-21 2020-03-24 레드힐 바이오파마 엘티디 Use of WX-UK1 and its prodrug WX-671 for the treatment of non-cancerous medical conditions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013061A1 (en) * 1996-09-24 1998-04-02 Cv Therapeutics, Inc. Inhibition of 26s and 20s proteasome by indanones
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
US5932567A (en) * 1995-02-10 1999-08-03 Basf Aktiengesellschaft Thrombin inhibitors
WO2000061608A2 (en) * 1999-04-09 2000-10-19 Basf Aktiengesellschaft Low-molecular inhibitors of complement proteases
US6358928B1 (en) * 1999-11-22 2002-03-19 Enzyme Systems Products Peptidyl sulfonyl imidazolides as selective inhibitors of serine proteases
WO2002053516A2 (en) * 2001-01-08 2002-07-11 Laboratoires Fournier Sa N(phenylsulphonyl)glycine derivatives and their therapeutic use
WO2003037892A1 (en) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
US5932567A (en) * 1995-02-10 1999-08-03 Basf Aktiengesellschaft Thrombin inhibitors
WO1998013061A1 (en) * 1996-09-24 1998-04-02 Cv Therapeutics, Inc. Inhibition of 26s and 20s proteasome by indanones
WO2000061608A2 (en) * 1999-04-09 2000-10-19 Basf Aktiengesellschaft Low-molecular inhibitors of complement proteases
US6358928B1 (en) * 1999-11-22 2002-03-19 Enzyme Systems Products Peptidyl sulfonyl imidazolides as selective inhibitors of serine proteases
WO2002053516A2 (en) * 2001-01-08 2002-07-11 Laboratoires Fournier Sa N(phenylsulphonyl)glycine derivatives and their therapeutic use
WO2003037892A1 (en) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUNGL AJ ET AL: "Time-Resolved Fluorescence Anisotropy of HIV-1 Protease Inhibitor Complexes Correlates with Inhibitory Activity", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA, US, vol. 37, 13 February 1998 (1998-02-13), pages 2778 - 2786, XP002191310, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
WO2003070229A2 (en) 2003-08-28
AU2003206945A1 (en) 2003-09-09
AU2003206945A8 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2002000860A3 (en) Novel proteases
YU17402A (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
WO2003097794A3 (en) Universal-tagged oligonucleotide primers and methods of use
SE0201980D0 (en) Novel compounds
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2003009855A3 (en) Organo-phosphorous compounds for activating gamma/delta t cells
IL172506A0 (en) New biological entities and the use thereof
WO2001083782A3 (en) Novel proteases
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
AU2003243097A1 (en) Novel compounds
WO2003070229A3 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
TR199902751T2 (en) Protease inhibitors.
WO2004087735A3 (en) Proteolytic and covalent antibodies
PL374080A1 (en) Processes for the preparation of fibrinogen
WO2004043379A3 (en) Chemical compounds
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
WO2003076391A3 (en) Urokinase inhibitors, production and use thereof
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
WO2004065406A3 (en) Rantes-derived peptides with anti-hiv activity
AU2003303076A1 (en) Cathepsin cysteine protease inhibitors and their use
WO2002094881A3 (en) Monoclonal antibody neutralising cathepsin b activity and uses thereof
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
AU2002362447A1 (en) Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
NO20053575D0 (en) Metal protease proteins
DE50309647D1 (en) NG FIBROTIC DISEASES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP